Martin Currie Ltd. Sells 27,481 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Martin Currie Ltd. lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 72,943 shares of the company’s stock after selling 27,481 shares during the period. IDEXX Laboratories comprises about 1.1% of Martin Currie Ltd.’s holdings, making the stock its 28th biggest position. Martin Currie Ltd.’s holdings in IDEXX Laboratories were worth $30,158,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in IDXX. Insight Wealth Strategies LLC raised its stake in shares of IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after buying an additional 7,041 shares in the last quarter. Geode Capital Management LLC raised its position in IDEXX Laboratories by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company’s stock worth $1,138,732,000 after purchasing an additional 40,349 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in IDEXX Laboratories during the third quarter worth about $1,263,000. Sax Wealth Advisors LLC boosted its holdings in IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock valued at $590,000 after purchasing an additional 617 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its stake in shares of IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock valued at $3,199,000 after purchasing an additional 800 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the topic of several recent analyst reports. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, March 25th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Finally, Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $415.87 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market capitalization of $33.71 billion, a P/E ratio of 38.98, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company’s 50 day simple moving average is $437.07 and its 200-day simple moving average is $442.90. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.